AstraZeneca saw 18% revenue growth in 2024, boosted by key drugs and global innovation. See here to know why we recommend a ...

Q4 2024 Earnings Call Transcript March 31, 2025 Operator: Good afternoon and welcome to INNOVATE Corp’s Fourth Quarter and ...

TransMedics' NOP advances organ transplantation with improved outcomes & cost reductions. See why I rate TMDX stock a strong ...

Reports Q4 revenue $236.6M vs. $361M last year…Reports DBM Global grew gross margin to 18.2% in the fourth quarter, an expansion of ...

Three experts explain how obstructive sleep apnea, an often-ignored cardiovascular risk factor, may affect your heart and treatment options.

Q4 2024 revenue of $1.5 million in pharma services; full year revenue of $1.9 millionGraftAssure RUO assay launched July ...

Good afternoon, and welcome to INNOVATE Corp's fourth quarter and full year 2024 earnings conference call. (Operator Instructions) Please note this event is being recorded. I would now like to turn ...

Beyond the guru holding structure, the company has a valid business model. As a leading provider of kidney care services ... percentages recently with gross margin of 32.9%, operating margin ...

Q4 2024 revenue of $1.5 million in pharma services; full year revenue of $1.9 millionGraftAssure RUO assay launched July ...

Jeffrey Graves; President, Chief Executive Officer, Director; 3D Systems Corp Jeffrey Creech; Chief Financial Officer, Executive Vice President; 3D Systems Corp Greetings, and welcome to the 3D ...

PAVmed Inc.  ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today provided a business ...

Research led by Children's Hospital of Fudan University in China has found that a gene called pancreatic progenitor cell ...